Disease block
C30-C39 – Bösartige Neubildungen der Atmungsorgane und sonstiger intrathorakaler Organe
- Chapter II: Neubildungen
86Decisions
154Patient groups
Added benefit by patient group
- Major3
- Considerable17
- Minor12
- Non-quantifiable6
- Not proven116
Diseases in this disease block
- C30 Bösartige Neubildung der Nasenhöhle und des Mittelohres 10 decisions
- C31 Bösartige Neubildung der Nasennebenhöhlen 10 decisions
- C32 Bösartige Neubildung des Larynx 10 decisions
- C33 Bösartige Neubildung der Trachea 7 decisions
- C34 Bösartige Neubildung der Bronchien und der Lunge 80 decisions
- C37 Bösartige Neubildung des Thymus 5 decisions
- C38 Bösartige Neubildung des Herzens, des Mediastinums und der Pleura 5 decisions
- C39 Bösartige Neubildung sonstiger und ungenau bezeichneter Lokalisationen des Atmungssystems und sonstiger intrathorakaler Organe 5 decisions
Decisions, newest first
Each decision lists only the patient groups coded with a disease in this disease block.
- 2026-06-18RetsevmoSelpercatinibNot proven: 2 of 2 patient groups
- 2026-05-21KeytrudaPembrolizumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2026-03-19TevimbraTislelizumabNot proven
- 2026-03-19TevimbraTislelizumabNot proven
- 2026-01-22ImfinziDurvalumabConsiderable
- 2026-01-22ImfinziDurvalumabNot proven
- 2025-12-04OpdivoNivolumabNot proven
- 2025-10-16HetroniflySerplulimabNon-quantifiable
- 2025-10-16AugtyroRepotrectinibNot proven: 2 of 2 patient groups
- 2025-10-16AugtyroRepotrectinibNot proven: 3 of 3 patient groups
- 2025-07-17RybrevantAmivantamabNot proven
- 2025-07-17LazcluzeLazertinibMinor
- 2025-07-17RybrevantAmivantamabNot proven: 2 of 2 patient groups
- 2025-07-17RybrevantAmivantamabMinor
- 2025-07-03TagrissoOsimertinibNot proven: 2 of 2 patient groups
- 2025-06-18TevimbraTislelizumabNot proven: 2 of 2 patient groups
- 2025-06-18TevimbraTislelizumabNot proven: 2 of 2 patient groups
- 2025-06-18TevimbraTislelizumabNot proven
- 2025-03-20TecentriqAtezolizumabConsiderable
- 2025-03-20BraftoviEncorafenibNot proven: 3 of 3 patient groups
- 2025-03-20MektoviBinimetinibNot proven: 3 of 3 patient groups
- 2025-03-20TecentriqAtezolizumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2025-02-06TagrissoOsimertinibNot proven
- 2025-01-16AlecensaAlectinibMajor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2024-12-19TagrissoOsimertinibMajor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2024-11-07RetsevmoSelpercatinibNot proven
- 2024-10-17KeytrudaPembrolizumabNot proven: 2 of 2 patient groups
- 2024-10-17KeytrudaPembrolizumabNot proven
- 2024-05-16EnhertuTrastuzumab deruxtecanNot proven: 2 of 2 patient groups
- 2024-02-06RozlytrekEntrectinibNot proven
- 2024-02-01OpdivoNivolumabNon-quantifiable
- 2023-10-19LibtayoCemiplimabNot proven: 2 of 2 patient groups
- 2023-10-05ImfinziDurvalumabNot proven: 2 of 2 patient groups
- 2023-10-05Tremelimumab AstraZenecaTremelimumabNot proven: 2 of 2 patient groups
- 2023-08-03LumykrasSotorasibNon-quantifiable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2023-02-02TabrectaCapmatinibNot proven: 3 of 3 patient groups
- 2022-09-01LorviquaLorlatinibNot proven
- 2022-09-01TepmetkoTepotinibNot proven: 3 of 3 patient groups
- 2022-08-04LumykrasSotorasibNot proven
- 2022-07-07RybrevantAmivantamabNot proven: 2 of 2 patient groups
- 2022-06-16GavretoPralsetinibNot proven: 5 of 5 patient groups
- 2022-01-20LibtayoCemiplimabNot proven
- 2021-11-19TecentriqAtezolizumabNot proven: 2 of 2 patient groups
- 2021-09-02RetsevmoSelpercatinibNot proven: 3 of 3 patient groups
- 2021-06-03YervoyIpilimumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2021-06-03OpdivoNivolumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2021-04-01ImfinziDurvalumabMinor
- 2021-02-18RozlytrekEntrectinibNot proven
- 2021-02-18RozlytrekEntrectinibNot proven
- 2020-10-15AlunbrigBrigatinibConsiderable: 1 of 2 patient groupsMinor: 1 of 2 patient groups
- 2020-08-20CyramzaRamucirumabNot proven: 2 of 2 patient groups
- 2020-05-14KeytrudaPembrolizumabConsiderable
- 2020-05-14KeytrudaPembrolizumabMinor
- 2020-04-02TecentriqAtezolizumabMinor
- 2020-04-02TecentriqAtezolizumabNot proven: 2 of 2 patient groups
- 2020-04-02VitrakviLarotrectinibNot proven
- 2020-04-02TecentriqAtezolizumabNot proven: 2 of 2 patient groups
- 2019-11-22LorviquaLorlatinibNot proven: 2 of 2 patient groups
- 2019-10-17VizimproDacomitinibNot proven: 2 of 2 patient groups
- 2019-09-19KeytrudaPembrolizumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2019-09-19KeytrudaPembrolizumabNon-quantifiable: 2 of 2 patient groups
- 2019-07-04AlunbrigBrigatinibNot proven
- 2019-04-04ImfinziDurvalumabConsiderable
- 2019-04-04KeytrudaPembrolizumabNot proven
- 2019-01-17TagrissoOsimertinibConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2018-06-21AlecensaAlectinibNon-quantifiable
- 2018-03-16TecentriqAtezolizumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2018-02-01ZykadiaCeritinibNot proven
- 2017-11-17OpdivoNivolumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2017-10-19TafinlarDabrafenibNot proven: 3 of 3 patient groups
- 2017-10-19MekinistTrametinibNot proven: 3 of 3 patient groups
- 2017-10-19TagrissoOsimertinibConsiderable
- 2017-10-19AlecensaAlectinibMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2017-08-03KeytrudaPembrolizumabConsiderable
- 2017-03-16XalkoriCrizotinibNot proven: 3 of 3 patient groups
- 2017-03-16ZykadiaCeritinibConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2017-02-02KeytrudaPembrolizumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2016-12-15XalkoriCrizotinibConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2016-10-20OpdivoNivolumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2016-10-20GiotrifAfatinibNot proven: 2 of 2 patient groups
- 2016-09-15TagrissoOsimertinibNot proven: 4 of 4 patient groups
- 2016-09-01CyramzaRamucirumabNot proven
- 2016-06-16XalkoriCrizotinibConsiderable
- 2016-02-04OpdivoNivolumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2015-11-05GiotrifAfatinibMajor: 1 of 5 patient groupsNot proven: 4 of 5 patient groups
- 2015-06-18VargatefNintedanibMinor
Data status: 2026-10-29